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ABSTRACT
Objectives In Europe, there is a distinction between two 
different healthcare organisation systems, the tax- based 
healthcare system (THS) and the social health insurance 
system (SHI). Our aim was to investigate whether the 
characteristics, treatment and mortality of older, critically 
ill patients in the intensive care unit (ICU) differed between 
THS and SHI.
Setting ICUs in 16 European countries.
Participants In total, 7817 critically ill older (≥80 years) 
patients were included in this study, 4941 in THS and 2876 
in the SHI systems.
Primary and secondary outcomes measures We chose 
generalised estimation equations with robust standard 
errors to produce population average adjusted OR (aOR). 
We adjusted for patient- specific variables, health economic 
data, including gross domestic product (GDP) and human 
development index (HDI), and treatment strategies.
Results In SHI systems, there were higher rates of frail 
patients (Clinical Frailty Scale>4; 46% vs 41%; p<0.001), 
longer length of ICU stays (90±162 vs 72±134 hours; 
p<0.001) and increased levels of organ support. The 
ICU mortality (aOR 1.50, 95% CI 1.09 to 2.06; p=0.01) 
was consistently higher in the SHI; however, the 30- day 
mortality (aOR 0.89, 95% CI 0.66 to 1.21; p=0.47) was 
similar between THS and SHI. In a sensitivity analysis 
stratifying for the health economic data, the 30- day 
mortality was higher in SHI, in low GDP per capita (aOR 
2.17, 95% CI 1.42 to 3.58) and low HDI (aOR 1.22, 95% CI 
1.64 to 2.20) settings.
Conclusions The 30- day mortality was similar in both 
systems. Patients in SHI were older, sicker and frailer 
at baseline, which could be interpreted as a sign for a 
more liberal admission policy in SHI. We believe that 
the observed trend towards ICU excess mortality in SHI 
results mainly from a more liberal admission policy and an 
increase in treatment limitations.
Trial registration numbers NCT03134807 and 
NCT03370692.
INTRODUCTION
Very old patients (often defined as being 80 
years of age or older) admitted to an inten-
sive care unit (ICU) have a high mortality.1 
Whether this group of patients will benefit 
from intensive care treatment is the subject of 
clinical studies and ethical debate.2 3 Never-
theless, older patients consume a dispropor-
tionate amount of intensive care resources, 
with questionable benefits on morbidity and 
mortality, which raises both socioeconomic 
and ethical questions of sustainability.4–6
There are numerous factors that influence 
outcome, age being only one of many.7–9 In 
addition to the severity of organ dysfunction, 
the patient’s functional and mental capacity 
prior to admission is of utmost importance.10 
Strengths and limitations of this study
 ► We performed a retrospective post hoc analysis of a 
European cohort of critically ill patients who are 80 
years and older.
 ► This study evaluated critically ill older (≥80 years) 
patients, 4941 in tax- based healthcare system and 
2876 in the social health insurance system systems 
from the VIP1 and VIP2 study.
 ► We compared baseline risk distribution using uni-
variate methods according to the distribution.
 ► We compared management and mortality outcomes 
using generalised estimation equations with robust 
standard errors to produce population average ad-
justed aOR.
 ► We performed multiple sensitivity analyses stratify-
ing 30- day mortality for patient- specific characteris-
tics, treatment strategies and health economic data.
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Multiple studies have confirmed the concept of frailty as 
a valuable tool, not only to assess the patient’s prehospital 
condition, but also to predict outcome.11–14
In addition to patient- specific factors, specific health-
care system characteristics, such as availability of resources, 
are hypothesised to influence the outcome of critically ill 
older patients.15 In Europe, a rough distinction is made 
between two healthcare systems; the tax- based health-
care system (THS) and the social health insurance system 
(SHI). There are other more nuanced classification 
systems with higher granularity used to divide the organ-
isation of healthcare systems.16–20 However, ultimately 
all subclassifications are variations of the initial subdivi-
sion into a primarily tax- financed, municipally organ-
ised system with a ‘single payer’ (THS) or into a social 
insurance system financed by predefined and earmarked 
premiums, mostly from payroll taxes, and organised in a 
more pluralistic way, often with the coexistence of both 
private and public service providers.21 A dichotomisation 
of the European healthcare system into THS versus SHI 
is therefore possibly an over- simplification, but it is never-
theless based on distinct differences.17 Other pragmatic 
analyses also use the same distinction, as well as the World 
Bank and the Organisation for European Economic 
Co- operation (OEEC).22 Differences in the treatment of 
older people between these two systems are likely, as the 
incentives for treating critically ill patients might differ 
between THS and SHI. In addition, differences in the 
way finances are allocated for elderly patients have been 
described.23
The VIP1 study evaluated 5021 critically ill patients 
over the age of 80 and showed that frailty assessed by the 
Clinical Frailty Scale (CFS) was associated with short- term 
mortality. The VIP2 study included acutely admitted 3920 
critically ill patients over the age of 79 and confirmed the 
association of CFS with short- term mortality.14 24
In this post hoc substudy of these two studies in very old 
intensive care patients (VIPs studies), we wanted to inves-
tigate whether the characteristics, management strategies 
(with a focus on organ support and treatment limitations) 
and mortality of older, critically ill patients in the ICU 
differed between THS and SHI.14 24 Since older patients 
in particular have a high probability of death, even after 
survival of the initial intensive care stay, we have evaluated 
not only the ICU mortality but also the 30- day mortality.3 
We hypothesised that patients differ significantly between 
THS and SHI with regards to baseline characteristics due 
to differing admission policies. Therefore, we speculated 
whether there were significant differences in the use of 
organ support and mortality rates between THS and SHI.
METHODS
Study subjects
VIP1 and VIP2 were prospective, multicentre studies, regis-
tered on  ClinicalTrials. gov.14 24 Both studies included very 
elderly VIPs, defined as patients aged 80 years or older. 
For VIP1, data were collected between October 2016 and 
February 2017. For VIP2, VIPs were included from May 
2018 to May 2019. Many countries could recruit patients 
without informed consent while some had to collect 
informed consent as the ethical consent procedures in 
Europe are diverse. For each patient baseline character-
istics (including age, gender, main reason for admission 
and frailty) and management strategies (including use 
of renal replacement therapy (RRT), mechanical venti-
lation, non- invasive ventilation (NIV) and rates of use of 
vasoactive drugs) were documented. Also, any treatment 
limitations (treatment withheld, or treatment withdrawn) 
were documented.
In this post hoc analysis of these two prospective trials, 
all patients admitted acutely (ie, non- electively) with 
complete data on age, gender, Clinical Frailty Score (CFS) 
and Sequential Organ Failure Assessment (SOFA) Score 
and ICU mortality were included.9 Patients were defined 
as being in a THS (Denmark, Great Britain, Sweden, 
Norway, Ireland, Italy, Spain, Portugal and Greece; 
n=4941) or SHI (Poland, Belgium, France, Germany, 
Netherlands, Austria and Switzerland; n=2876) health-
care system. We used the dichotomisation used by the 
World Bank and the OEEC.22 The primary endpoint of 
this study was ICU mortality, and the secondary endpoints 
were 30- day mortality and rates of treatment limitation. 
The data on 30- day mortality was available for only 7443 
patients (THS n=4712; SHI n=2731). Frailty was assessed 
by the CFS and the respective visual and simple descrip-
tions were used with permission.25–27 For the patients 
recruited to the VIP2 trial, Katz activities of daily living 
(Katz ADL) with ADL Score≤4 defining disability and 
short form of Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE), with IQCODE ≥3.5 
describing cognitive decline and Co- morbidity and Poly-
pharmacy Score were assessed.25–27 The gross domestic 
product (GDP) per capita for 2019 in US$ was retrieved 
from the International Money Fund,28 the human devel-
opment index (HDI) from the United Nations Develop-
ment Program,29 and the total (compulsory, voluntary, 
out- of- pocket) amount of health spending per capita in 
US$ in 2019 from the Organisation for Economic Co- op-
eration and Development.30 The number of ICU beds 
were obtained from a previous publication.31
Patient and public involvement
No patient involved.
Statistical analysis
We assessed continuous variables for distribution using 
Kolmogorov–Smirnov test. Normally distributed contin-
uous data are given as mean±SD and compared using 
Student’s t- test. Non- normally distributed continuous 
data are given as median±IQR and compared using 
Mann’s U- test. Categorical data are given as numbers 
(percentage) and compared using the χ test.
The primary exposure was being in a THS versus SHI. The 
data are likely to be clustered on an ICU level. Therefore, 
a multilevel regression approach was chosen. As the health 
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economic data do not vary within a given cluster, we chose 
generalised estimation equations (GEE) with robust stan-
dard errors to produce population average ORs. The survival 
analysis/GEE- based analyses were conducted using only 
robust estimators of the standard errors and not in the sense 
of robustness against violations of normality assumptions as 
for the robust methods (eg, Mann–Whitney tests) used for 
the univariate analyses. Model-1 includes only the ICU as 
panel. Model-2 includes patient specific factors (sex, age per 
year, SOFA Score per point, Frailty Score per CFS point and 
the admission diagnosis). Model-3 adds the health economic 
data (GDP per capita, HDI, health spending per capita and 
ICU beds per capita). Model-4 adds the treatment strategies 
(treatment limitations and organ support) and calculates 
only mortality. Adjusted aOR and respective 95% CI were 
obtained. Sensitivity analyses stratifying 30- day mortality for 
patient- specific characteristics (figure 1), treatment strat-
egies (figure 2) and health economic data (figure 3) were 
done. Risk model calibration accuracy/goodness of fit was 
evaluated graphically by stratification of patients into SOFA 
quartiles and comparison of observed versus expected events 
within risk strata (figure 4). All tests were two sided, and a p 
value of <0.05 was considered statistically significant. Stata/IC 
V.16.1 was used for all statistical analyses.
RESULTS
Baseline risk distribution in SHI versus THS
In total, 7817 patients from 16 European countries 
were included in this study. The relative frequencies of 
the admission diagnoses varied between THS and SHI 
Figure 1 Sensitivity analyses stratifying 30- day mortality for 
patient- specific characteristics using generalised estimation 
equations producing population average ORs. The depicted 
aORs from model-1 include only the intensive care unit (ICU) 
as panel. The 30- day mortality was similar between tax- 
based healthcare system (THS) and health insurance system 
(SHI) in male (aOR 1.26, 95% CI 0.98 to 1.61), frail (aOR 1.15, 
95% CI 0.998 to 1.710), non- frail (aOR 1.15, 95% CI 0.88 to 
1.52), nonagenarian (aOR 1.27, 95% CI 0.81 to 2.02) patients. 
There was a higher mortality in SHI in octogenarian (aOR 
1.29, 95% CI 1.10 to 1.59) and female (aOR 1.32, 95% CI 1.02 
to 1.70) patients and in patients staying below 72 hours (aOR 
1.41, 95% CI 1.08 to 1.85).
Figure 2 Sensitivity analyses stratifying 30- day mortality for 
treatment strategies using generalised estimation equations 
producing population average ORs. The depicted aORs from 
model-1 include only the intensive care unit as panel. The 30- 
day mortality was similar in patients with renal replacement 
therapy (RRT), without vasoactive drugs, intubated and non- 
intubated paitents and patients on non- invasive ventilation 
(NIV). There was a trend towards higher 30- day mortality in 
patients without RRT (aOR 1.29, 95% CI 1.04 to 1.60) and 
without NIV (aOR 1.50, 95% CI 1.16 to 1.94). SHI, health 
insurance system; THS, tax- based healthcare system.
Figure 3 Sensitivity analyses stratifying 30- day mortality for 
health economic data using generalised estimation equations 
producing population average ORs. The depicted aORs from 
model-1 include only the intensive care unit (ICU) as panel. 
The 30- day- mortality was higher in SHI, in settings with low 
ICU beds per capita (aOR 2.17 95%CI 1.57-3.02), low gross 
domestic product (GDP) per capita (aOR 2.17 95% CI 1.42-
3.58) and low human development index (HDI) (aOR 1.22 
95% CI 1.64-2.20), as well as in high total health spending 
settings. SHI, health insurance system; THS, tax- based 
healthcare system.
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systems (table 1). There were higher rates of nonagenar-
ians (11% vs 9%; p=0.002) in SHI systems. The country 
specific differences within the systems are descriptively 
shown in online supplemental tables 1 and 2.
The rates of frail patients (CFS>4; 46% vs 41%; p<0.001), 
as well as patients with disabilities (ADL <5; 30% vs 24%; 
p<0.001)) and cognitive decline (IQCODE≥3.5; 37% vs 
29%; p<0.001), were higher in the SHI compared with 
THS. The length of ICU stay was higher (90±162 vs 
72±134 hours; p<0.001) in the SHI (table 1).
Organ support and management in SHI versus THS
The rates of NIV use were similar in model-1 and model-3 
and showed a trend towards higher odds in the THS 
(table 2). The rates of RRT were consistently higher in 
the SHI in all models (table 2; model-3 aOR 1.89, 95% CI 
1.27 to 2.82; p=0.002).
The crude rates for withholding treatment (34% vs 
26%) were higher in SHI systems. This finding persisted 
in model-1 (aOR 1.44, 95% CI 1.09 to 1.90; p=0.01) 
but not after adjustment for patient- specific variable in 
model-2 and after adjustment for the health economic 
data in model-3 (aOR 1.10, 95% CI 0.78 to 1.53; p=0.59; 
table 2).
Mortality analysis
The overall ICU mortality was 27% and the 30- day 
mortality was 41%. The ICU mortality was consistently 
higher in the SHI systems, after adjustment for patient- 
specific variables in model-2, health economic data in 
model-3 and in model-4 integrating patient- specific data, 
health economic data as well as treatment strategies (aOR 
1.50 95% CI 1.09 to 2.06; p=0.01). However, the 30- day 
mortality was similar between THS and SHI in all models 
(table 2).
Sensitivity analyses
In sensitivity analyses, stratifying 30- day mortality for 
patient- specific characteristics (figure 1), treatment strat-
egies (figure 2) we observed no differences in 30- day 
mortality between THS and SHI, except for a trend 
towards higher mortality (aOR 1.41, 95% CI 1.08 to 
1.85) in patients staying below 72 hours in the ICU in 
SHI. However, in the sensitivity analyses stratifying for the 
health economic data (figure 3), the 30- day mortality was 
higher in SHI, in settings with a low number of ICU beds 
per capita (aOR 2.17, 95% CI 1.57 to 3.02), low GDP per 
capita (aOR 2.17, 95% CI 1.42 to 3.58) and low HDI (aOR 
1.22, 95% CI 1.64 to 2.20), as well as in high total health 
spending settings.
In the graphical calibration analysis both THS and SHI 
showed agreement for predicted ICU mortality proba-
bility and observed events in SOFA risk quartiles, both in 
all patients (figure 4A) and in patients without any treat-
ment limitation (figure 4B).
DISCUSSION
The aim of our study was to investigate possible differ-
ences in the characteristics, management and outcome 
of VIPs between THS and SHI healthcare systems. In 
general, critically ill patients admitted to ICUs in SHI were 
older, frailer and more frequently suffered from cogni-
tive impairment. All the health economic data, including 
the health spending per capita and the ICU beds avail-
able per capita, we evaluated were higher in THS. We 
were able to detect trends towards a more liberal use of 
organ support, especially RRT, in SHI. ICU mortality was 
higher in SHI even after adjustment for confounders, 
while 30- day mortality showed no difference. There was 
a relatively consistent trend towards excess mortality in 
poorer SHI systems, which could be interpreted as there 
Figure 4 Risk model calibration accuracy/goodness of fit 
was evaluated graphically by stratification of patients into 
Sequential Organ Failure Assessment (SOFA) quartiles (Q1: 
SOFA 0–4; Q2:>4–7; Q3>7–10, Q4>10) and comparison of 
observed versus expected events within risk strata. In the 
graphical calibration analysis, both tax- based healthcare 
system (THS) and health insurance system (SHI) showed 
agreement of predicted intensive care unit (ICU) mortality 
probability and observed events in SOFA risk quartiles, 
both in all patients (A) and in patients without any treatment 
limitation (B).
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Table 1 Baseline characteristics of the cohort
n=4941 n=2876
Female sex n (%) 2282 (46) 1418 (49) 0.008
Age (years)
Median (±IQR) 84 (5) 84 (5) <0.001
Age >90 n (%) 450 (9) 324 (11) 0.002
Frailty Score—CFS
Median (±IQR) 4 (3) 4 (3) <0.001
Frailty (CFS>4) n (%) 2008 (41) 1317 (46) <0.001
ADL*
Median (±IQR) 6 (1) 6 (2) 0.03
Disablitiy (ADL≤4) 462 (24) 446 (30) <0.001
IQCODE*
Median (±IQR) 3.19 (0.61) 3.25 (0.75) <0.001
Cognitive decline (IQCODE ≥3.5) n (%) 460 (29) 493 (37) <0.001
SOFA Score
Median (±IQR) 7 (6) 7 (6) 0.006
SOFA quartiles 0.007
SOFA 0–4 n (%) 1514 (31) 844 (30)
SOFA 5–7 n (%) 1277 (26) 747 (26)
SOFA 8–10 n (%) 1090 (23) 608 (21)
SOFA>10 n (%) 972 (20) 667 (23)
ICU length of stay (hours)
Median (±IQR) 72 (134) 90 (162) <0.001
ICU stay <72 hours n (%) 2476 (50) 1299 (45) <0.001
CPS*
Median (±IQR) 10 (7) 11 (7) 0.10
Admission diagnosis
Respiratory failure 1128 (23) 772 (27) <0.001
Circulatory failure 657 (13) 423 (15) 0.08
Combined circulatory and respiratory failure 535 (11) 352 (12) 0.06
Sepsis 693 (14) 354 (12) 0.03
Multitrauma without head injury 92 (2) 55 (2) 0.98
Multitrauma with head injury 87 (2) 58 (2) 0.42
Head injury 117 (2) 78 (3) 0.35
Intoxication 13 (<1) 23 (<1) 0.001
Cerebral injury (non- traumatic) 286 (6) 212 (7) 0.006
Emergency surgery 694 (14) 239 (8) <0.001
Other 637 (13) 310 (11) 0.006
Economic data
Health spending per capita (US$)
Median (±IQR) 4653 (1626) 5376 (389) <0.001
HDI
Median (±IQR) 0.92 (0.05) 0.89 (0.04) <0.001
GDP per capita (US$)
Median (±IQR) 41 030 (18 295) 41 760 (8262) <0.001
ICU beds
Median (±IQR) 6.6 (2.0) 11.6 (5.2) <0.001
*Only available in VIP2 study.
ADL, activities of daily living; CFS, Clinical Frailty Scale; CPS, Co- morbidity and Polypharmacy Score; GDP, gross domestic product; HDI, human development 
index; ICU, intensive care unit; IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly; SHI, social heath insurance system; SOFA, Sequential Organ 
Failure Assessment; THS, tax- based health service.
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being an advantage in having a THS system in precarious 
settings where there are limited resources.
Baseline risk distribution in SHI versus THS
We interpret our findings that patients admitted to ICUs 
in SHI were older, frailer and more frequently suffered 
from cognitive impairment, as perhaps suggesting a more 
liberal admission policy in SHI. Intensivists in THS might 
need to apply a more stringent and strict triage criterion 
prior to ICU admission, as SHI had a higher number of 
ICU beds per capita. While in the THS, the allocation of 
resources is primarily centralised and, for example, based 
on quality- adjusted life year for specific procedures, in the 
SHI there is a coexistence of public and private owner-
ship of hospitals.17 This gives rise to two possible explana-
tions of the differences observed. First, the coexistence of 
public and private providers could lead to an excess (from 
the THS point of view) of poorly evidence- based health-
care interventions for economic reasons resulting in the 
wrong incentives for patient care. Second, the focus on 
financial constraints and resulting therapeutic and equip-
ment limitations in the THS (from the SHI point of view) 
could lead to a restriction on admission and treatment, 
especially to subgroups of patients (such as the elderly). 
The verification of one of these two considerations is 
beyond the scope of this paper.
Organ support and management in SHI versus THS
The rates of RRT were consistently higher in SHI, but this 
broader application of organ support did not translate 
into a superior 30- day mortality compared with the more 
restrictive approach in THS. In our opinion, this could be 
interpreted as an indication of a more resource- efficient 
approach to patient care in THS. That this, presumably 
more economically favourable strategy, resulted in no 
detriment to patient outcome is interesting and poten-
tially thesis generating.
The decision to restrict treatment based on a predicted 
individual prognosis is not an easy clinical task, even 
in older, critically ill patients.32 33 We observed a trend 
towards more therapy limitation in SHI systems in the 
unadjusted analysis, but this signal disappeared after 
adjustment for health economic data. This signal could 
also have been interpreted as an excess of ICU beds in 
SHI. If one assumes that people in THS and SHI systems 
are of the same age with similar severity of illness, an 
increase in treatment goal limitations in SHI systems 
could indicate an overly liberal allocation of intensive 
care resources, especially when the outcomes are similar. 
It could then be assumed that patients with limitations 
on ceilings of care in the THS are not primarily treated 
in intensive care (and thus in a resource- saving manner).
Mortality analysis
The trend we have observed towards ICU excess mortality 
in SHI would also fit this explanation but could also be 
interpreted as an indication of worse quality of care in 
SHI. We, however, interpret this trend towards higher 
ICU mortality in SHI systems as the result of a more 
liberal admissions policy due to the increased availability 
of ICU beds. This interpretation is supported by the fact 
that in the ICU mortality analysis stratified according to 
the SOFA Score (figure 4), excess mortality in the SHI was 
primarily detected in the highest quartile (SOFA >10)—
this quartile is also overrepresented in the SHI (23% vs 
20%). This could be due to a higher rate of ‘futile’ admis-
sions, which were a priori not associated with clinical 
benefit. In other words, selection and triage, both by no 
means an easy task, in the THS may take place prior to 
ICU admission and in SHI during the ICU admission.6 34 
We are, however, aware, that triage is not only a clinical 
but also an ethical challenge. Interestingly, the THS 
showed a trend towards higher rates of ‘short- term’ ICU 
stays (arbitrary cut- off at 72 hours). Again, this finding 
can be interpreted in a number of ways. On the one 
hand, this could primarily reflect the overall lower (and 
thus more resource efficient) duration of ICU stays in the 
THS. On the other hand, it could reflect a higher rate of 
‘ICU trials’, that is, admissions to ICUs with the rationale 
to try a curative therapy trial for two to 2–3 days. At this 
point, the prognosis is re- evaluated, and if continuing the 
current treatment is deemed futile, there is a change in 
the goal of therapy and the patient is discharged from 
ICUs to receive ongoing care on a normal ward.35
After careful adjustment for possible confounders, we 
did not observe differences in the 30- day mortality. Why 
the better survival data at the time of ICU discharge in 
the THS do not translate into better outcomes at 30 days 
is beyond the scope of the present study. It could reflect 
different care for older patients in the THS (for example, 
because fewer geriatric or rehabilitation medical 
resources are available). If one accepted our consider-
ations from above regarding triage, the THS may ulti-
mately fail to translate the initially better patient selection 
into better long- term outcomes. This could underline the 
importance of geriatric treatment, especially after survival 
of an acute intensive care event. Intensive care certainly 
contributes to survival of the acute event, but only 
specialist geriatric treatment and rehabilitation might be 
able to translate this into better long- term outcomes. We 
can only speculate at this point about the morbidity rate, 
which is likely to also benefit from specialist geriatric care 
and rehabilitation.36
The pronounced increase in mortality from 27% on 
ICU discharge to 41% at 30 days could reflect the high 
well documented known mortality of older, critically ill 
patients.2 3 Systematic factors such, as national healthcare 
frameworks, or even patient- specific treatment strategies 
and therapy concepts could become less relevant in a 
group of very old patients as the age- associated mortality 
inherent in humans and the observed mortality could 
simply be an expression of the natural dying process.
Sensitivity analyses
In the sensitivity analysis, there was a signal that patients 
with a shorter length of stay had a higher mortality in SHI 
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ICUs. Therefore, although in SHI hospitals more patients 
are admitted to ICU, they die relatively quickly. One 
possible explanation for this is that in THS ICUs these 
patients are never admitted, as when triaged for admis-
sion to ICU they are deemed unsuitable and therefore 
palliated on the wards.
There was a trend towards higher 30- day mortality, in 
the sensitivity analyses, in countries with lower GDP, lower 
HDI and lower numbers of ICU beds available in the SHI. 
The relatively consistent trend towards excess mortality 
in lower GDP SHI could be an expression of the relative 
superiority of a THS in settings with limited resources. 
Future public health studies could test this hypothesis, as 
it has potential consequences, for example, in assisting 
developing countries (with limited resources) that are 
building a new health system.
Limitations
This retrospective, post hoc study has several limitations. 
First, we are aware that the division between THS and 
SHI is an over- simplification and that mixed systems 
exist, especially in some countries such as Austria and 
Portugal. Further, we categorised the countries into SHI 
versus THS, but there may be country- specific and even 
site- specific differences within the two health systems. 
We have shown these differences for the primary and 
secondary endpoints in the online supplemental tables. 
These differences are presented in a descriptive manner 
as the absolute numbers in the countries are relatively 
low and not suitable for a formal statistical analysis. Other 
national or local factors that could influence our results 
are religious/cultural differences and expectations of 
family members. Unfortunately, we do not have any data 
on these potential confounders. Ultimately, we believe 
that the division into primarily directly tax- financed 
systems with strong state control (THS) or indirectly 
financed social insurance systems (SHI) is justified.
Another limitation is the potential selection bias. The 
30- day endpoint was not available for all patients, which 
may have led to a selection bias. Furthermore, we have no 
specific information on local, national or inbuilt admis-
sion algorithms. For example, patients treated in SHI 
systems on ICUs (and triaged in the course of an ICU 
trial) may well be treated in THS intermediate care units 
not primarily managed by intensive care physicians and 
thus not included in the study data, which could also lead 
to selection bias.
Furthermore, in some areas our data lacks granularity. 
There are no data on functional capacity and morbidity, 
or management (discharge to home or institution), and/
or staffing ratios. Also, no data are available on the char-
acteristics or absolute or relative frequencies of patients 
refused ICU admission. Despite this, we do have data on 
the baseline frailty and functional capacity for a signifi-
cant number of critically ill patients and we think that our 
results add a novel insight into the differences between 
public healthcare systems.
Lastly, we are well aware of the limitations of sensitivity 
and subgroup analyses, which limit the generalisability of 
the conclusions drawn (figures 1–3). We chose to report 
these results to help generate ideas for future public 
health analyses. Despite all the limitations we consider 
our analysis to be a solid foundation for further studies 
comparing ICU management and its outcomes in both 
the THS and SHI healthcare settings.
Conclusion
To conclude, the adjusted 30- day mortality was similar in 
both systems. Patients in SHI were older, sicker and frailer 
which could be interpreted as a sign of a more liberal 
admission policy in SHI. We believe that the observed 
trend towards ICU excess mortality in SHI results mainly 
from a more liberal admission policy and an increased 
use of treatment limitations.
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Supplemental Table 1                
  Austria Belgium France Germany Netherlands Poland Switzerland 
Outcome        
ICU mortality 29 (28) 22 (14) 302 (31) 86 (17) 105 (17) 301 (48) 17 (10) 
30-day-mortality 41 (43) 40 (28) 387 (40) 136 (29) 186 (33) 336 (57) 35 (21) 
Treatment limitation               
Treatment withhold 38 (37) 46 (29) 374 (38) 73 (14) 297 (49) 103 (16) 66 (39) 
Treatment witdraw 13 (13) 18 (11) 166 (17) 58 (11) 107 (18) 35 (6) 18 (11) 
Management strategies        
NIV  n (%) 43 (41) 21 (13) 341 (35) 162 (32) 65 (11) 64 (10) 59 (35) 
Mechanical ventilation  n (%) 36 (34) 53 (34) 491 (50) 238 (47) 270 (45) 560 (87) 58 (35) 
Vasoactive drugs  n (%) 47 (45) 66 (42) 454 (46) 323 (63) 337 (56) 519 (81) 73 (44) 
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Primary and secondary outcomes for the specific countries in SHI.  
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Supplemental Table 2                   
  Denmark Spain Greece Ireland Italy Norway Portugal Sweden UK 
Outcome          
ICU mortality 52 (19) 73 (14) 155 (40) 38 (20) 279 (28) 81 (18) 105 (26) 102 (19) 382 (20) 
30-day-mortality 104 (39) 124 (24) 184 (50) 61 (33) 375 (49) 181 (39) 151 (40) 221 (41) 567 (31) 
Treatment limitation                   
Treatment withhold 132 (49) 116 (22) 36 (9) 47 (25) 106 (11) 190 (41) 76 (19) 271 (51) 325 (17) 
Treatment witdraw 32 (12) 52 (10) 11 (3) 32 (17) 106 (11) 83 (18) 52 (13) 101 (19) 284 (15) 
Management strategies          
NIV  n (%) 92 (34) 97 (18) 45 (12) 42 (22) 173 (18) 168 (36) 80 (20) 157 (29) 409 (22) 
Mechanical ventilation  n (%) 111 (41) 201 (38) 342 (88) 123 (64) 709 (72) 138 (30) 230 (57) 225 (42) 655 (35) 
Vasoactive drugs  n (%) 163 (60) 224 (42) 335 (86) 142 (74) 409 (41) 286 (62) 216 (54) 332 (62) 987 (52) 
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Primary and secondary outcomes for the specific countries in THS.  
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